TS
CRNX icon

Thomas Steyer’s Crinetics Pharmaceuticals CRNX Stock Holding History

Thomas Steyer’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336M Buy
8,989,098
+651,000
+8% +$24.2M 1.55% 22
2026
Q1 		$303M Buy
8,338,098
+1,405,000
+20% +$62.8M 1.59% 22
2025
Q4 		$323M Buy
6,933,098
+1,163,000
+20% +$51.8M 1.4% 26
2025
Q3 		$240M Buy
5,770,098
+1,124,000
+24% +$35.9M 0.98% 34
2025
Q2 		$134M Buy
4,646,098
+41,000
+0.9% +$1.27M 0.56% 42
2025
Q1 		$154M Buy
4,605,098
+530,000
+13% +$19.8M 0.74% 41
2024
Q4 		$208M Buy
4,075,098
+2,913,098
+251% +$163M 0.91% 38
2024
Q3 		$59.4M Buy
1,162,000
+665,000
+134% +$34.3M 0.26% 59
2024
Q2 		$22.3M Buy
497,000
+492,000
+9,840% +$22.7M 0.1% 71
2024
Q1 		$234K Sell
5,000
-117,904
-96% -$4.61M ﹤0.01% 140
2023
Q4 		$4.37M Sell
122,904
-239,000
-66% -$7.33M 0.02% 95
2023
Q3 		$10.8M Buy
+361,904
New +$7.46M 0.05% 86
2019
Q1 		– Sell
-95,365
Closed -$2.86M – 98
2018
Q4 		$2.86M Sell
95,365
-46,450
-33% -$1.31M 0.02% 92
2018
Q3 		$4.06M Buy
+141,815
New +$4.21M 0.02% 93

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thomas Steyer's CRNX Position: Q2 2026 in Review

Thomas Steyer increased its Crinetics Pharmaceuticals (CRNX) stake by 7.8% in Q2 2026, buying an estimated $24.2M and bringing the position to 8,989,098 shares worth $336M. The position accounts for 1.55% of the portfolio, ranked #22.

Thomas Steyer first reported a position in CRNX in Q3 2018 and has held it in 14 quarters since. 264 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Thomas Steyer held 8,989,098 shares of Crinetics Pharmaceuticals worth $336M as of Q2 2026.
  • Thomas Steyer bought 651,000 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $24.2M.
  • Crinetics Pharmaceuticals made up 1.55% of Thomas Steyer's portfolio in Q2 2026, its #22 holding.
  • Thomas Steyer first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 14 quarters since.
  • 264 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.